Drug Profile
CMV-specific T cell therapy - Juno Therapeutics
Alternative Names: CMV-Streptacells - Juno Therapeutics; STAGE CMV-StreptacellsLatest Information Update: 15 May 2019
Price :
$50
*
At a glance
- Originator Stage Cell Therapeutics
- Developer Juno Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 15 May 2019 Discontinued - Phase-I/II for Cytomegalovirus infections treatment in Germany (IV) (Juno Therapeutics pipeline, May 2019)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 11 May 2015 Stage Cell Therapeutics has been acquired by Juno Therapeutics